<DOC>
	<DOCNO>NCT01889056</DOCNO>
	<brief_summary>The blood hormone Erythropoietin ( Epo ) produce kidney also brain , especially hypoxic condition . It show animal study human study Epo neuroprotective property . Furthermore , scientific evidence central modulatory effect Epo brain high dose Epo need overcome blood brain barrier . In double blind placebo control crossover study investigate effect single high dose Epo cognitive function exercise capacity healthy subject . The subject receive single high dose Epo ( 60.000 IU ) perform computerize cognitive test battery , breathe test , maximal exercise capacity test ( VO2max ) , time trial ( TT ) 24 hour treatment . The primary outcome study cognitive function . - Trial medicinal product</brief_summary>
	<brief_title>Non-erythroid Effects Erythropoietin Cognitive Function Exercise Capacity Humans</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Inclusion criterion : Healthy Subjects ; Age 18 35 year ; Normal body weight ( body mass index &gt; = 18.5 kg/m2 &lt; = 24.9 kg/m2 ) ; Nonsmokers ( &gt; = 1 year ) ; VO2max &lt; = 55 ml/kg/min female &lt; = 60 ml/kg/min male ; Exclusion criterion : Persons abnormal Serum Ferritin level accord gender dependent reference value GCPcertificated laboratory ; Persons preexist genetic hemostatic disorder ( Factor V Leiden mutation , Prothrombin mutation ) ; Persons risk deep venous thrombosis ( e.g . history venous thromboembolic event ) ; Persons hematocrit value &gt; 55 % ; Persons expose prolong ( &gt; = 5 day ) high altitude ( &gt; = 2500m Normal Null ) &lt; = 6 month prior begin study ; Persons willing maintain living condition study period ( e.g . prepare certain competition ) ; Contraindications class drug study , e.g . know hypersensitivity allergy class drug investigational product ; Pregnant breast feed woman ; Intention become pregnant course study ; Lack safe contraception ; Treatment investigational product ; Known suspect noncompliance , drug alcohol abuse ; Inability follow procedure study , e.g . due language problem , psychological disorder ; Participation another study investigational drug within 30 day precede present study ; Enrolment investigator , his/her family member , employee dependent person ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Cognition</keyword>
	<keyword>Exercise</keyword>
</DOC>